1. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile–based classification 
Laura K. Ferris, MD, PhD, Aaron S. Farberg, MD, Brooke Middlebrook, BS, Clare E. Johnson, RN, Natalie Lassen, PhD, Kristen M. Oelschlager, RN, Derek J. Maetzold, BS, Robert W. Cook, PhD, Darrell S. Rigel, MD, Pedram Gerami, MD 
Journal of the American Academy of Dermatology 
Volume 76, Issue 5, Pages e3 (May 2017)
DOI: /j.jaad
Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Study summary. Prognosis was determined for 205 stage I and II melanoma cases using either the GEP test or AJCC Individualized Melanoma Patient Outcome Prediction Tool. Binary risk groups were determined for the GEP and AJCC prognostic tools, and the GEP predictor was compared with the online predictor with either a 79% or 68% cutoff score as the boundaries between AJCC low and high risk. AJCC, American Joint Committee on Cancer; CM, cutaneous melanoma; GEP, gene expression profile.
Journal of the American Academy of Dermatology  , e3DOI: ( /j.jaad )
Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
Combined GEP and AJCC prediction of risk for distant metastasis and death. Kaplan-Meier analysis was performed to compare RFS (A), DMFS (B), and (C) OS for 4 subgroups of cases with concordant or discordant risk prognosis according to the GEP and AJCC 79% cutoff predictions. Pie charts compare gene expression profiling with AJCC 79% in the subset of cases with a metastasis or death, and indicate that over 25% of cases with events had discordant risk prediction with the 2 tests. Significantly different from: ∗class 1/AJCC low risk; †class 1/AJCC high risk; ‡class 2/AJCC low risk; §class 2/AJCC high risk. AJCC, American Joint Committee on Cancer; DMFS, distant metastasis-free; GEP, gene expression profile; OS, overall survival; RFS, recurrence-free.
Journal of the American Academy of Dermatology  , e3DOI: ( /j.jaad )
Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions